classified as: favorable (t, [15, 17] , t, [8, 21] , or sole ly inv16); unfavorable (−5, −7, or complex [≥3] abnormalities), or intermediate (all others) ac cording to the Southwest Oncology Group. 20, 21 Samples were collected from all newly diagnosed AML patients younger than 60 years, but to pre serve the uniformity of the study group, patients with favorable cytogenetic outcome owing to dif ferent biology and result of specific treatment, were excluded from the study. Patients were treat ed at the Hematology Department of the Medi cal University of Bialystok, Poland, with a stan dard therapy for patients younger than 60 years, based on the Polish Adult Leukemia Group proto col.
22 They underwent a 7 day induction therapy, in which cytarabine (200 mg/m 2 ) was adminis tered as a continuous IV infusion for 7 consecu tive days; daunorubicin (60 mg/m 2 ) was admin istered for 3 consecutive days as an IV push; and cladribine (5 mg/m 2 ) was administered for 5 days also as an IV push. 22 Patients who achieved com plete remission were given 2 consolidation thera pies (1st HAM: cytarabine [1.5 g/m 2 IV, 1-3 days] and mitoxantrone [10 mg/m 2 IV, 3-5 days] and 2nd HDArC as a high dose of cytarabine [4 g/ m 2 /d IV in 1, 3, 5 day]) prior to hematopoietic stem cell transplantation. The median follow up of patients from day 1 of induction therapy was 233 days (min., 5; max., 1958) .
The control group consisted of 90 age and sex matched healthy subjects.
Plasma was separated from EDTA peripher al blood samples by centrifuging the samples at 5000 rpm for 10 min. Plasma samples obtained from all study subjects were aliquoted and stored at −70°C until the analysis. measurements of selected parameters hsP70 western blot analysis The recombinant human HSP70 anti gen (Sigma, United States) was used in the analysis. Protein was heated at 70°C for 10 min in a reducing sample buffer, separated on 4%-12%NuPage™Bis Tris gel (Invitrogen, Carlsbad, California, United States) and transferred to a nitrocellulose mem brane (Invitrogen) using the Trans Blot SD trans fer apparatus. Following transfer, membranes were incubated in a blocking buffer (5% nonfat dry milk plus Tris buffered saline containing 0.05%Tween 20, TBS T) for 1 h at room temperature and in cubated for 1 h with the patients' plasma dilut ed at 1:100 in a blocking buffer. As a positive con trol, anti human HSP70 antibody (EKS 750 P2 kit, Stressgen Biotechnologies, San Diego, California, United States), membranes were washed 4 times for 10 min in TBS T, and then incubated for 1 h with peroxidase conjugated goat antihuman im munoglobulin G (IgG, KPL, Gaithersburg, Mary land, United States) diluted at 1:5000. Following incubation with secondary antibodies, membranes were washed 4 times for 10 min in TBS T and de veloped in 3,3',5,5' tetramethylbenzidine substrate for 10 to 15 min. At the end of color development, the substrate was removed and reaction stopped by washing the membrane with deionized water. cytolytic attack mediated by natural killer cells. 14,15 Although HSP70 is expressed mainly in the cy tosol and membranes in the cells, an increas ing number of data have demonstrated its ac tive extracellular secretion stimulated either by cellular necrosis or via an active stress induced pathway. As such, it has a wide range of significant extracellular functions, and, in addi tion, it may well act as a signal that warns the im mune system of potential danger. 12,1618 Further more, the HSP70 membrane phenotype can also be used as a prognostic indicator of overall pa tient survival in many types of cancer including leukemia. As previous studies have shown, high er HSP70 levels, assessed in mononuclear cells from the peripheral blood and bone marrow as well as in the circulating protein, indicate a poor prognosis for leukemia patients. 19, 20 On the oth er hand, there are no data to determine the level and importance of antiHSP antibodies.
The aim of the study was to evaluate the lev els of anti HSP70 antibody and HSP 70 antigen in the peripheral blood of patients with acute my eloid leukemia (AML) , and to analyze clinical and prognostic relevance of the findings.
PATIENTs ANd mEThOds Patients and samples
The general characteristics of the patients with AML are listed in TAbLE 1. All samples from patients with AML and healthy control subjects were col lected after the protocol (No. R I002/218/2007) had been approved by the local ethics commit tee and a written informed consent had been obtained from all subjects. Pathological condi tions, based on the examination of peripheral blood and bone marrow samples, were classified according to the French-American-British (FAB) classification. Flow cytometry, molecular study, and cytogenetic and fluorescence in situ hybrid ization were performed, reviewed, and classi fied likewise. A cytogenetic status of AML was HSP70 antibodies in a prospectively identified cohort of 80 patients with AML. Patients with AML had a significantly high er concentration of anti HSP70 antibodies com pared with healthy controls (354.62 ±21.3 pg/ml and 247.59 ±16.04 pg/ml, respectively, P = 0.007). The mean percentage of HSP70 antigen concen tration (relative to controls) in AML patients was 109.81% ±10.17%.
Correlation with clinical and laboratory data We evaluated the association of the HSP70 concen tration with several clinical and hematological variables. In patients with AML, no difference between the mean values of HSP70 antigen in the groups with an intermediate and unfavorable cytogenetic risk was noted (119.16% ±17.36% and 103.13% ±11.08%, respectively, P = 0.7). Complete response was obtained in 44 of 80 patients (55%). The study did not show any significant associa tions between the baseline HSP70 antigen level and the type of response after induction chemo therapy. The HSP70 antigen level in the group of AML patients with complete remission (CR) was 98.19% ±1.73%, and in the remaining patients (no CR), it was 118.84% ±16.47%, P = 0.55.
We subsequently correlated HSP70 with a se lection of well known parameters of prognosis and tumor load in AML (TAbLE 2) . The study did not show any significant correlations with lac tate dehydrogenase (LDH) and white blood cell count (WBC). The HSP70 level did not correlate with age, sex, the amount of blast cells in the pe ripheral blood and bone marrow, or cluster of dif ference (CD) markers (TAbLE 2) .
The analyses of anti HSP70 antibodies in patients with AML did not reveal any signif icant differences between the concentration of anti HSP70 antibodies in the group of pa tients with intermediate and unfavorable cy togenetic risk (3029.83 ±29.51 pg/ml and 384.56 ±32.05 pg/ml, respectively, P = 0.23). Ad ditionally, no differences in the concentration of anti HSP70 antibodies associated with the type of response after induction treatment were ob served. The mean concentration of anti HSP70 an tibodies in CR patients showed be roughly equal to that of non CR patients (350.86 ±32.69 pg/ml and 357.53±28.77 pg/ml, respectively, P = 0.88). Furthermore, the anti HSP70 antibody concen tration did not correlate significantly with any parameters of prognosis and tumor load in AML (TAbLE 2) .
Although cytogenetic grouping did not corre late with the HSP70 antigen or its antibody in pa tients with AML, those with a low anti HSP70 an tibody concentration had a considerably shorter survival (P = 0.03; FIGuRE 1). The median surviv al was 127 days for patients with a lower base line anti HSP70 antibody concentration than the median (354.62 pg/ml). The median surviv al of AML patients with a higher concentration of anti HSP antibodies than the median was not reached at the time of the analyses. Of note, no
The control group for Western blot was pooled plasma of healthy volunteers. Antigen concentra tions in individual patients are shown as a per centage (%) concentration of antigen pooled plas ma controls.
detection of antihuman hsP70 IgG/A/m antibodies
by an enzyme -linked immunosorbent assay Quan titative determination of antihuman HSP70 an tibodies in the plasma was done using a commer cial test kit (anti HSP70 Elisa Kits, Stressgen Bio technologies, USA) in accordance with the man ufacturer's instructions. statistical analysis Descriptive statistics as well as univariate and multivariate analyses were per formed. Relationships between continuous vari ables were assessed using Spearman rank corre lations. The χ 2 or Kruskal-Wallis test was used to assess the relationships between categorical variables. The Kaplan-Meier plots of survival were performed separately for each group. Cut off points used for Kaplan-Meier plots were me dians for each group. Survival curves were com pared using the Cox's F test. A multivariate anal ysis using a multiple logistic regression was per formed to predict mortality. All P values were 2 tailed and considered statistically significant at a value of less than 0.05.
REsuLTs Patients
We studied 80 adult patients with de novo AML before induction chemothera py. There were 49 men and 31 women. The medi an age was 48 years (range, 18-60 years). Accord ing to the FAB classification, 5 patients were iden tified as M0, 4 as M1, 39 as M2, 17 as M4, 15 as M5. A chromosomal analysis was performed in all patients. Patient characteristics are present ed in TAbLE 1.
The study showed no significant differences ei ther in the mean anti HSP70 antibody concen tration or in the HSP70 antigen level in the dif ferent subgroups of AML (P = 0.34 and P = 0.58, respectively).
high concentrations of anti -hsP70 and hsP70 antigen in acute myeloid leukemia We measured the plas ma concentration of HSP70 antigen and anti epithelium, as well as lung carcinomas and astro cytomas. 24 HSP70 has also been proved to be in volved in increased cell proliferation (breast, uter ine cervix, lung), lymph node metastasis (breast, colon), increased tumor size (uterine, cervix), the presence of mutated p53 (breast, endome trium), and a higher clinical stage (oral, colon, melanoma). 24 Moreover, high HSP70 levels pre dicted a lower response of breast cancers to ra diation and hyperthermia, 25 as well as resistance to conventional treatment with dexamethasone in multiple myeloma cells. 26 Few data are available regarding the expression or concentration of HSPs in AML.
19,27 Thomas et al. 19 reported that leukemic cells showed a het erogeneous pattern of HSP70 expression. The ex pression assessed by flow cytometry ranged from 3% to 97% (median, 34%) among patients and was not specific to any subtype of AML. The anal ysis showed that the expression of HSP70 on blasts of less than 20% correlated with higher CR rates and longer overall survival. The expres sion was not different between the subgroups with favorable and unfavorable cytogenetic risk. Furthermore, it was established that HSP70 pro tein positively correlated with the BCL2 oncop rotein. The study group did not receive uniform treatment but the authors postulated that worse prognosis, in term of the overall survival, might be a consequence of elevated antiapoptotic pro tein expression.
Our study was performed in a cohort of AML patients receiving uniform treatment and we assessed circulating HSP70 antigen. The analy sis showed a higher amount of HSP70 protein in AML individuals than in healthy controls. Al though the level of HSP70 protein in the periph eral blood may correlate with intracellular expres sion, 28 and therefore with overall survival, we did differences in survival were found in patients with AML according to the median HSP70 antigen level (109.81%). The median survival for patients with higher level than the median was 69 days com pared with 214 days for patients with lower lev els (P = 0.15; FIGuRE 2).
A multivariate analysis was performed to assess the effect of HSP70 protein and antiHSP70 an tibodies on the risk of death in the study group. The logistic regression analysis revealed that a higher HSP70 protein concentration and low er anti HSP70 antibody level predicted death with a relative risk of 8.5 (95% confidence interval, 1.8-39.2, P = 0.022). These 2 parameters were the best predictors of the alive/dead status of pa tients in the study group (R 2 = 0.379).
dIsCussION Normal development of hemato poietic cells and maintenance of tissue homeo stasis require a relatively tight regulation of pro liferation, differentiation, and death processes. Any minor deregulation of the above can result in leukemia.
23 Abnormal HSP expression has recent ly been reported to disrupt cellular development, which draws particular attention to HSP70 as a potential anticancer target. HSPs are overex pressed in a wide range of human cancers and are implicated in tumor cell proliferation, differ entiation, invasion, metastasis, death, and rec ognition by the immune system. Although HSP levels are not informative at the diagnostic level, they are more restricted molecular markers that are quite useful in diagnostic immunopathology and carcinogenesis. On the other hand, the cir culating levels of HSP and anti HSP antibodies in cancer patients may be helpful in tumor diag nosis. Furthermore, some studies have shown an association between HSPs and poor differen tiation in cancers of the breast, ovary, and oral of HSP90 and its co chaperone, HSP70.
29 Un fortunately, in our study, molecular tests did not reveal the FLT3 ITD mutation in any of the pa tients; therefore, we cannot confirm or disprove the above findings. 29 Although high intracellular HSP70 levels con tribute to cell protection mechanisms, the tumor specific membrane associated HSP70 expres sion has been shown to function as a dan ger signal that can increase the immunogenic ity of a tumor and induce natural killer cell and cytotoxic T lymphocyte responses. 13,30 More im portantly, the secretion of HSP70 has shown to be the consequence of immune responses, thus placing HSP70 among the dominant antigens rec ognized by the immune system. HSP70 released from tumor cells may allow the transfer of anti genic peptides to antigen presenting cells or may enhance the ability of antigenpresenting cells to process and present tumor antigens to specific T cells, thereby augmenting the immune respons es.
31,32 Thus, the plasma anti HSP70 antibody con centration could also indicate both innate and adaptive immunity as well as tumor load.
The first report of antibodies against HSPs in a human disease is that of Jarjour et al.,
33 who suggested that the difference between the levels of anti HSPs antibodies seen in the blood of pa tients with various rheumatoid and other inflam matory diseases and that of normal controls could merely reflect disease associated polyclonal B cell activation.
33 Since then, a few investigations on the presence of anti HSPs antibodies in the tu mor process have been conducted. For example, Conroy et al., 34 showed that antibodies against HSPs, including HSP70, were detectable in pa tients with breast cancer, and suggested that in creased levels of antibodies to HSP27 were cor related with an improved survival rate, whereas not notice any statistically significant prolonga tion of the overall survival in the group with a low er HSP70 concentration. On the other hand, we observed a better median overall survival in that group but lack of statistical significance may be related to the limited number of patients. Fur thermore, logistic regression showed the effect of the HSP70 concentration on the alive/dead status that could reflect a prognostic value of this param eter. We did not observe a different HSP70 concen tration according to cytogenetic grouping, which is consistent with the study by Thomas et al. 19 Circulating HSP of HSP70 in myeloid neo plasms had previously been analyzed by Yeh et al. 20 Similar to our study, their study revealed that AML patients had a high plasma level of the HSP70 antigen in contrast to healthy con trols. Moreover, patients with higher circulat ing HSP70 levels had a significantly shorter sur vival compared with the remaining study popu lation. The authors did not show significant dif ferences in the concentration between the sub groups with different cytogenetic risk but revealed that the HSP70 antigen positively correlated with such risk factors as WBC, β 2 microglobulin, and LDH, which have a known prognostic value and are associated with adverse outcomes in AML. 20 In contrast, our study did not show any correla tions with the above prognostic factors.
The effect of HSP70 on overall survival shown in previous studies may have other explana tion than that postulated by Thomas et al. 19 As shown in a recent study by Reikvam et al., 29 pa tients harboring an FLT3 internal tandem du plication (FLT3 ITD) were extensively overrep resented in the cluster with high HSP levels, in dicating a strong dependence of HSPs in stabi lizing FLT3 ITD encoded oncoproteins. More over, FLT3 ligation further increased the levels high levels of antibodies to HSP90 were corre lated with a reduced survival rate. 34 Korneeva et al. 35 also reported that there was a common prev alence of anti HSP27 IgA (but not IgG) antibod ies in the genital tract of women with endometri al and ovarian cancer before and after treatment.
Our study demonstrated a higher concentra tion of anti HSP70 antibodies in AML patients in comparison with healthy controls. Additional ly, it did not show any differences in the baseline concentration of anti HSP70 in the subgroups of different cytogenetic risk, and did not reveal any statistical differences in the concentration of the antiHSP70 antibody and the response rate. However, we showed a significantly longer over all survival in patients with a higher concentra tion of anti HSP70 antibody in contrast to pa tients with a lower concentration of the protein at the time of diagnosis. Furthermore, our multi variate analysis revealed that the anti HSP70 an tibody concentration together with the plasma HSP70 level were the best predictors of the alive/ dead status in patients with AML. The study did not show any correlation between the anti HSP concentration and laboratory parameters linked with tumor mass.
In conclusion, the expression of HSP70 in patients with AML may play a role in the resis tance of cancer cells to immune mediated de struction. However, in some patients, this could stimulate an immune response that may contrib ute to the fight against malignant cells and pro mote better overall outcome of therapy. It still remains unclear whether extracellular HSP70 is released as a free soluble protein, in detergent soluble membrane vesicles, or in HSP70 peptide complexes, and whether it regulates the role of antibodies in response to the antigen. Further research is needed to determine the nature and form of the HSP70 antibodies and antigen. Nev ertheless, their clinical significance as an adverse prognostic indicator of survival in patients with AML in our study is remarkable. Additional anal yses are necessary to better understand the role of anti HSP70 antibodies and HSP70 antigen in the prognosis of leukemia and prediction of ther apeutic response.
